| Identification | Back Directory | [Name]
Ginsenoside Rb3 | [CAS]
68406-26-8 | [Synonyms]
NH25835
Gypenoside IV
xylopyranosyl-
GINSENOSIDE RB3
GINSENOSIDE Rb3(SH)
Ginsenoside Rb3 ,98%
Ginsenoside Rb3
Gypenoside IV
Ginsenoside Rb3 (CAS#68403-26-8)
hydroxydammar-24-en-20-yl6-O-β-D-
β-D-Glucopyranoside, (3β,12β)-3-[(2-O-β-D-
Ginsenoside Rb3, 98%, from Panax ginseng C. A. Mey.
glucopyranosyl)oxy)-12-hydroxydammar-24-en-20-yl6-o-beta-d-xylopyranosyl-
(3-beta,12-beta)-3-((2-o-beta-d-glucopyranosyl-beta-d-alpha-d-glucopyranosid
(3β,12β)-3-[(2-O-β-D-Glucopyranosyl-β-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-20-yl 6-O-β-D-xylopyranosyl-β-D-glucopyranoside
β-D-Glucopyranoside, (3β,12β)-3-[(2-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-20-yl 6-O-β-D-xylopyranosyl-
[3β-[[2-O-(β-D-Glucopyranosyl)-β-D-glucopyranosyl]oxy]-12β-hydroxy-5α-dammar-24-en-20-yl]6-O-(β-D-xylopyranosyl)-β-D-glucopyranoside
b-D-Glucopyranoside, (3b,12b)-3-[(2-O-b-D-glucopyranosyl-b-D-glucopyranosyl)oxy]-12-hydroxydammar-24-en-20-yl 6-O-b-D-xylopyranosyl-
(2S,3R,4S,5S,6R)-2-[[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(10R,12S,14R)-12-hydroxy-4,4,10,14-tetramethyl-17-[(E,2R)-6-methyl-2-[[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R)-3,4 | [Molecular Formula]
C53H90O22 | [MDL Number]
MFCD00221756 | [MOL File]
68406-26-8.mol | [Molecular Weight]
1079.27 |
| Chemical Properties | Back Directory | [Melting point ]
193～195℃ | [Boiling point ]
1117.1±65.0 °C(Predicted) | [density ]
1.42±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly), Pyridine (Slightly) | [form ]
neat | [pka]
12.85±0.70(Predicted) | [color ]
White | [Water Solubility ]
insoluble in water | [Stability:]
Hygroscopic | [CAS DataBase Reference]
68406-26-8 |
| Hazard Information | Back Directory | [Uses]
Ginsenoside Rb3 inhibits the upregulation of phospho-IκB-α and nuclear translocation of NF-κB subunit p65 induced by glucose deprivation then reperfusion. | [in vivo]
Ginsenosides Rb3 is a major compound isolated from Gynostemma pentaphyllum that holistically improves gut microenvironment and induces anti-polyposis in ApcMin/+ mice. Six-weeks-old mice are subjected to Rb3 treatment, before the appearance of the intestinal polyps. All the mice are monitored for food intake, water consumption, and weight changes. Throughout the experiment, no Rb3/Rd-associated weight loss in mice is observed. In addition, none of the treated mice show variations in food and water consumption. Whereas, the number and size of the polyps are effectively reduced by Rb3 treatments[3]. | [IC 50]
NF-κB: 8.2 μM (IC50, in 293T cell lines); iNOS; COX-2 |
|
|